BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026
Go back to BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026| BIOLINE RX SP ADR (NASDAQ: BLRX) | Delayed: 2.82 -0.04 (1.4%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.86 | 52 Week High | $1.63 | |||
| Open | $2.86 | 52 Week Low | $0.71 | |||
| Day High | $3.04 | P/E | N/A | |||
| Day Low | $2.82 | EPS | $0.00 | |||
| Volume | 2,697 | |||||
| BIOLINE RX SP ADR (NASDAQ: BLRX) | Delayed: 2.82 -0.04 (1.4%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.86 | 52 Week High | $1.63 | |||
| Open | $2.86 | 52 Week Low | $0.71 | |||
| Day High | $3.04 | P/E | N/A | |||
| Day Low | $2.82 | EPS | $0.00 | |||
| Volume | 2,697 | |||||
